drugset / Trial / NCT04355689
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
Phase 1/2
Completed
49 enrolled
Nacuity Pharmaceuticals, Inc.
Foundation Fighting Blindness · collabNacuity Pharmaceuticals, PTY LTD · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.
Timeline
- Start
- 2020-09-03
- Primary completion
- 2025-06-20
- Completion
- 2026-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-Acetylcysteine Amide | Unknown | 250 mg | Oral |